{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017778","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.320665+00:00","generated_at":"2026-06-08T19:48:29.735015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved","bullets":["Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.","CIMERLI net sales $40.0M (+50% QoQ); UDENYCA net sales $33.0M (+4% QoQ); YUSIMRY launched with $1.4M Q3 sales.","FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for nasopharyngeal carcinoma; commercial launch expected Q1 2024.","Closed Surface Oncology acquisition on Sep 8, adding clinical-stage anti-IL-27 and anti-CCR8 I-O pipeline assets.","UDENYCA ONBODY BLA resubmitted Oct 4; potential approval late 2023 or early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017778","json":"https://secwatch.observer/filing/0001558370-23-017778.json","markdown":"https://secwatch.observer/filing/0001558370-23-017778.md","text":"https://secwatch.observer/filing/0001558370-23-017778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/0001558370-23-017778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/chrs-20231106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:48:29.735015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dde3a8d21fcbc99fa2f73e0156f0365c2d1a03a5","claim":"Coherus Oncology, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/0001558370-23-017778-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}